2386 East Mall, Suite 100
Vancouver, British Columbia
Canada V6T 1Z3
Phone: 604-221-8478

Frank Holler, president and CEO
Privately Held


Xenon Genetics Inc. is a clinical genomics company engaged in identifying genes and other drug targets associated with human disease and developing pharmaceutical therapies based on these genetic targets.

The company uses multiple strategies to identify novel genes and drug targets in its drug discovery research. These strategies use both human genetics and comparative genomics approaches, which include the study of multiple founder populations; the study of rare syndromes and extreme forms of disease phenotypes using Extreme Genetics technology; the study of protective or opposite phenotypes in which the phenotype represents a drug surrogate; and the use of comparative genomics including animal models.

Xenon in October 2001 acquired all assets of QuantaNova Canada Ltd., a subsidiary of Scotia Holdings plc, of Stirling, UK, related to its lipid metabolism drug discovery program, which will be used in developing novel therapeutics for diabetes, obesity and cardiovascular disease. The assets include an intellectual property portfolio of novel genes representing potential new drug targets, proprietary drug screening and diagnostic assays, as well as biological materials, radiochemicals and a lipid reference library.

Xenon in November 2000 acquired Montreal-based RGS Genome Inc.


Drug discovery agreement to provide high-throughput screening, chemistry and informatics services to Xenon’s drug discovery program: Discovery Partners International Inc.

License and preclinical research program for lipoprotein lipase LPL gene therapy: Amsterdam Molecular Therapeutics BV.

Corporate partnership to develop new drug therapies to raise HDL cholesterol for patients with low levels of HDL cholesterol: Warner-Lambert Co.

An international network of clinical institutions and physicians provides Xenon with exclusive access and intellectual property rights to DNA and clinical databases. Xenon has entered into 24 agreements providing access to 31 clinical populations around the world.